Expanding roles for leukotrienes in airway inflammation

Current Allergy and Asthma Reports

Volumn 8, Issue 4, 2008, Pages 367-373

  Peters Golden, Marc ^a  

^a Division of Pulmonary and Critical Care Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PRANLUKAST; VERLUKAST; ZAFIRLUKAST; ZILEUTON; ANTIASTHMATIC AGENT; LEUKOTRIENE B4 RECEPTOR; LTB4R PROTEIN, HUMAN;

ALLERGIC ASTHMA; ANTIGEN PRESENTATION; ASTHMA; BRONCHOSPASM; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; ENDOTHELIUM CELL; EOSINOPHILIA; HUMAN; IMMUNE RESPONSE; LUNG FIBROSIS; MAST CELL; NEUTROPHIL CHEMOTAXIS; NEUTROPHILIA; NONHUMAN; PATHOGENESIS; RESPIRATORY TRACT INFLAMMATION; REVIEW; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; RESPIRATORY SYSTEM;

ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; INFLAMMATION; LEUKOTRIENES; RECEPTORS, LEUKOTRIENE B4; RESPIRATORY SYSTEM;

EID: 50349094226     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-008-0057-z     Document Type: Review

References (62)

1. Peters-Golden M, Henderson W Jr: Leukotrienes. N Engl J Med 2007, 357:1841-1854.
2. Zhu J, Qiu YS, Figueroa DJ, et al.: Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa. Am J Respir Cell Mol Biol 2005, 33:531-540.
3. Woszczek G, Chen LY, Nagineni S, et al.: Leukotriene D4 induces gene expression in human monocytes through cysteinyl leukotriene type I receptor. J Allergy Clin Immunol 2008, 121:215-221.
4. Ichiyama T, Kajimoto M, Hasegawa M, et al.: Cysteinyl leukotrienes enhance tumour necrosis factor-alpha-induced matrix metalloproteinase-9 in human monocytes/macrophages. Clin Exp Allergy 2007, 37:608-614.
5. Jiang Y,IKanaoka Y, Feng C, et al.: Cutting edge: interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene-induced signaling. J Immunol 2006, 177:2755-2759.
6. Wong WS, Zhu H, Liao W: Cysteinyl leukotriene receptor antagonist MK-571 alters bronchoalveolar lavage fluid proteome in a mouse asthma model. Eur J Pharmacol 2007, 575:134-141.
7. Kim DC, Hsu FI, Barrett NA, et al.: Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation. J Immunol 2006, 176:4440-4448.
8. Stelmach I, Bobrowska-Korzeniowska M, Majak P, et al.: The effect of montelukast and different doses of budesonide on IgE serum levels and clinical parameters in children with newly diagnosed asthma. Pulm Pharmacol Ther 2005, 18:374-380.
9. Okunishi K, Dohi M, Nakagome K, et al.: A novel role of cysteinyl leukotrienes to promote dendritic cell activation in the antigen-induced immune responses in the lung. J Immunol 2004, 173:6393-6402.
10. Thivierge M, Stankova J, Rola-Pleszczynski M: Toll-like receptor agonists differentially regulate cysteinyl-leukotriene receptor 1 expression and function in human dendritic cells. J Allergy Clin Immunol 2006, 117:1155-1162.
11. Robbiani D, Finch R, Jager D, et al.: The leukotriene C4 transporter MRP1 regulates CCL19 (MIP-3b, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000, 103:757-768.
12. Parameswaran K, Liang H, Fanat A, et al.: Role for cysteinyl leukotrienes in allergen-induced change in circulating dendritic cell number in asthma. J Allergy Clin Immunol 2004, 114:73-79.
13. Lamoureux J, Stankova J, Rola-Pleszczynski M: Leukotriene D4 enhances immunoglobulin production in CD40-activated human B lymphocytes. J Allergy Clin Immunol 2006, 117:924-930.
14. Spinozzi F, Russano AM, Piattoni S, et al.: Biological effects of montelukast, a cysteinyl-leukotriene receptor-antagonist, on T lymphocytes. Clin Exp Allergy 2004, 34:1876-1882.
15. Prinz I, Gregoire C, Mollenkopf H, et al.: The type 1 cysteinyl leukotriene receptor triggers calcium influx and chemotaxis in mouse alpha beta-and gamma delta effector T cells. J Immunol 2005, 175:713-719.
16. Henderson W Jr, Tang L-O, Chu S-J, et al.: A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 2002, 165:108-116.
17. Muz MH, Deveci F, Bulut Y, et al.: The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model. Exp Mol Med 2006, 38:109-118.
18. Lee KS, Kim SR, Park HS, et al.: Cysteinyl leukotriene upregulates IL-11 expression in allergic airway disease of mice. J Allergy Clin Immunol 2007, 119:141-149.
19. Henderson WR Jr, Chiang GK, Tien YT, Chi EY: Reversal of allergen-induced airway remodeling by cysLT1 receptor blockade. Am J Respir Crit Care Med 2006, 173:718-728.
20. Peters-Golden M, Bailie M, Marshall T, et al.: Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002, 165:229-235.
21. Failla M, Genovese T, Mazzon E, et al.: Pharmacological inhibition of leukotrienes in an animal model of bleomycininduced acute lung injury. Respir Res 2006, 7:137.
22. Kelly MM, Chakir J, Vethanayagam D, et al.: Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest 2006, 130:741-753.
23. Kato J, Kohyama T, Okazaki H, et al.: Leukotriene D4 potentiates fibronectin-induced migration of human lung fibroblasts. Clin Immunol 2005, 117:177-181.
24. Yoshisue H, Kirkham-Brown J, Healy E, et al.: Cysteinyl leukotrienes synergize with growth factors to induce proliferation of human bronchial fibroblasts. J Allergy Clin Immunol 2007, 119:132-140.
25. Schmidt M, Sun G, Stacey MA, et al.: Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003, 171:380-389.
26. Vannella KM, McMillan TR, Charbeneau RP, et al.: Cysteinyl leukotrienes are autocrine and paracrine regulators of fibrocyte function. J Immunol 2007, 179:7883-7890.
27. Figueroa DJ, Borish L, Baramki D, et al.: Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis. Clin Exp Allergy 2003, 33:1380-1388.
28. Mita H, Hasegawa M, Saito H, Akiyama K: Levels of cysteinyl leukotriene receptor mRNA in human peripheral leucocytes: Significantly higher expression of cysteinyl leukotriene receptor 2 mRNA in eosinophils. Clin Exp Allergy 2001, 31:1714-1723.
29. Corrigan C, Mallett K, Ying S, et al.: Expression of the cysteinyl leukotriene receptors cysLT1 and cysLT2 in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J Allergy Clin Immunol 2005, 115:316-322.
30. Fujii M, Tanaka H, Abe S: Interferon-gamma up-regulates expression of cysteinyl leukotriene type 2 receptors on eosinophils in asthmatic patients. Chest 2005, 128:3148-3155.
31. Mellor EA, Frank N, Soler D, et al.: Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R. Proc Natl Acad Sci U S A 2003, 100:11589-11593.
32. Early SB, Barekzi E, Negri J, et al.: Concordant modulation of cysteinyl leukotriene receptor expression by IL-4 and IFN-gamma on peripheral immune cells. Am J Respir Cell Mol Biol 2007, 36:715-720.
33. Beller TC, Maekawa A, Friend DS, et al.: Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J Biol Chem 2004, 279:46129-46134.
34. Uzonyi B, Lotzer K, Jahn S, et al.: Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells. Proc Natl Acad Sci U S A 2006, 103:6326-6331.
35. Thompson C, Cloutier A, Bosse Y, et al.: Signaling by the cysteinyl-leukotriene receptor 2: Involvement in chemokine gene transcription. J Biol Chem 2008, 283:1974-1984.
36. Pillai SG, Cousens DJ, Barnes AA, et al.: A coding polymorphism in the cysLT2 receptor with reduced affinity to LTD4 is associated with asthma. Pharmacogenetics 2004, 14:627-633.
37. Jiang Y, Borrelli LA, Kanaoka Y, et al.: CysLT2 receptors interact with cysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells. Blood 2007, 110:3263-3270.
38. Klotsman M, York TP, Pillai SG, et al.: Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 2007, 17:189-196.
39. Ciana P, Fumagalli M, Trincavelli ML, et al.: The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 2006, 25:4615-4627.
40. Wenzel SE, Szefler SJ, Leung DY, et al.: Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997, 156:737-743.
41. Kostikas K, Gaga M, Papatheodorou G, et al.: Leukotriene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma. Chest 2005, 127:1553-1559.
42. Tager AM, Bromley SK, Medoff BD, et al.: Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003, 4:982-990.
43. Miyahara N, Swanson BJ, Takeda K, et al.: Effector CD8+ T cells mediate inflammation and airway hyper-responsiveness. Nat Med 2004, 10:865-869.
44. Miyahara N, Takeda K, Miyahara S, et al.: Requirement for leukotriene B4 receptor 1 in allergen-induced airway hyperresponsiveness. Am J Respir Crit Care Med 2005, 172:161-167.
45. Terawaki K, Yokomizo T, Nagase T, et al.: Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J Immunol 2005, 175:4217-4225.
46. Islam SA, Thomas SY, Hess C, et al.: The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. Blood 2006, 107:444-453.
47. Weller CL, Collington SJ, Brown JK, et al.: Leukotriene B4, an activation product of mast cells, is a chemoattractant for their progenitors. J Exp Med 2005, 201:1961-1971.
48. Iikura M, Suzukawa M, Yamaguchi M, et al.: 5-Lipoxygenase products regulate basophil functions: 5-oxo-ETE elicits migration, and leukotriene B4 induces degranulation. J Allergy Clin Immunol 2005, 116:578-585.
49. Heller EA, Liu E, Tager AM, et al.: Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 2005, 112:578-586.
50. Chupp GL, Lee CG, Jarjour N, et al.: A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007, 357:2016-2027.
51. Reese TA, Liang HE, Tager AM, et al.: Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature 2007, 447:92-96.
52. Peters-Golden M: Do anti-leukotriene agents inhibit asthmatic inflammation? Clin Exp Allergy 2003, 33:721-724.
53. Peters-Golden M, Henderson WR Jr: The role of leukotrienes in allergic rhinitis. Ann Allergy Asthma Immunol 2005, 94:609-618; quiz 618-620, 669.
54. Wenzel SE, Trudeau JB, Kaminsky DA, et al.: Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995, 152:897-905.
55. Pizzichini E, Leff J, Reiss T, et al.: Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial. Eur Respir J 1999, 14:12-18.
56. Kane G, Pollice M, Kim C, et al.: A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 1996, 97:646-654.
57. Sandrini A, Ferreira IM, Gutierrez C, et al.: Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma. Chest 2003, 124:1334-1340.
58. Bisgaard H, Loland L, Anhoj J: NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999, 160:1227-1231.
59. Montuschi P, Mondino C, Koch P, et al.: Effects of montelukast treatment and withdrawal on fractional exhaled nitric oxide and lung function in children with asthma. Chest 2007, 132:1876-1881.
60. Larsson BM, Kumlin M, Sundblad BM, et al.: Effects of 5-lipoxygenase inhibitor zileuton on airway responses to inhaled swine house dust in healthy subjects. Respir Med 2006, 100:226-237.
61. Jayaram L, Duong M, Pizzichini MM, et al.: Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma. Eur Respir J 2005, 25:41-46.
62. Hasday J, Meltzer S, Moore W, et al.: Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. Am J Respir Crit Care Med 2000, 161:1229-1236.